Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings
Optomed Plc Stock Exchange Release 30 April 2021 at 9.30, Helsinki
Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings
Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from BI Asset Management Fondsmægler-selskab A/S (“BIAM”). According to the notification, the total holdings in Optomed shares and votes held by BIAM has increased to 5.69 % per cent of all of the registered shares in Optomed on 28 April 2021.
The total number of the Company’s registered shares amounts to 14,003,144 shares. Each share entitles to one vote.
The total position of BIAM subject to the notification:
| % of shares and voting rights (total of A) | % of shares and voting rights through financial instruments (total of B) | Total of both in % (A+B) | |
| Resulting situation on the date on which threshold was crossed or reached | 5.69 % | - | 5.69 % |
| Position of previous notification (if applicable) | - | - | - |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
| Class/type of sharesISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) |
Indirect (SMA 9:6 ja 9:7) |
Direct (SMA 9:5) |
Indirect (SMA 9:6 ja 9:7) |
|
| FI4000410881 | 796,773 | - | 5.69 % | - |
| SUBTOTAL A | 796,773 | 5.69 % | ||
Information in relation to the person subject to the notification obligation as contained in the notification
The complete chain of controlled undertakings through which the shares, voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
| BI Asset Management Fondsmægler-selskab A/S | - | - | - |
| Kapitalforeningen Unite II, Europæiske Small Cap Aktier KL | 2.51 % | - | 2.51 % |
| Investeringsforeningen BankInvest, Europa Small Cap Aktier KL | 3.18 % | - | 3.18 % |
Further enquiries
Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com, +358(0)50 562 4077.
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 56 international patents protecting the technology.